A 24-week double-blind placebo-controlled study of the efficacy and safety of the AMPA modulator S47445 in patients with mild to moderate Alzheimer's disease and depressive symptoms.

Katy Bernard,Sylvie Gouttefangeas,Sylvie Bretin, Stéphanie Galtier, Philippe Robert,Vjera Holthoff-Detto,Jeffrey Cummings,Maria Pueyo

Alzheimer's & Dementia: Translational Research & Clinical Interventions（2019）

引用 16|浏览10

暂无评分

摘要

S47445 administered for 24 weeks was safe and well tolerated by patients with mild to moderate AD; the compound did not show significant benefits over placebo on cognition, function, or depressive symptoms.

查看译文

关键词

Alzheimer's disease,Positive allosteric AMPA modulator,Glutamate,Depressive symptoms,Neuropsychiatric symptoms

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要